Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.80 CAD
Change Today -0.03 / -3.61%
Volume 37.0K
HEM On Other Exchanges
Symbol
Exchange
Venture
OTC US
Toronto
Frankfurt
As of 11:44 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

hemostemix inc (HEM) Snapshot

Open
C$0.80
Previous Close
C$0.83
Day High
C$0.85
Day Low
C$0.80
52 Week High
12/24/14 - C$1.25
52 Week Low
11/27/14 - C$0.55
Market Cap
52.5M
Average Volume 10 Days
14.5K
EPS TTM
--
Shares Outstanding
65.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HEMOSTEMIX INC (HEM)

Related News

No related news articles were found.

hemostemix inc (HEM) Related Businessweek News

No Related Businessweek News Found

hemostemix inc (HEM) Details

Hemostemix Inc., a clinical-stage biotechnology company, focuses on developing, manufacturing, and commercializing blood-derived autologous cell therapies to treat severe medical disorder. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, an angiogenic cell precursor that is in phase II clinical trial used for the treatment of critical limb ischemia. It also produces various types of cells and cellular products, such as neural cell precursors and bone cell precursors. The company is headquartered in Surrey, Canada.

Founded in 2014

hemostemix inc (HEM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$48.4K
Chief Financial Officer
Total Annual Compensation: C$34.7K
Executive Chairman and Corporate Secretary
Total Annual Compensation: --
Vice President of Research and Development
Total Annual Compensation: C$135.0K
Compensation as of Fiscal Year 2014.

hemostemix inc (HEM) Key Developments

Hemostemix Inc. Announces International Phase-2 Clinical Trial for Critical Limb Ischemia

Hemostemix Inc. announced that in its international phase-2 clinical trial for critical limb ischemia (CLI): enrollment of its 20th patient. The double-blind, randomized, placebo-controlled trial currently recruits participants at six sites in Canada and South Africa under the same clinical protocol and will ultimately enroll approximately 100 participants with CLI. The trial studies the efficacy of the company's lead product, ACP-01, which uses angiogenic progenitor cells to combat the life-threatening complications of CLI. These proprietary cells are grown from a patient's own blood and, once injected into his or her diseased tissue, are able to support the formation of new blood vessels.

Hemostemix Inc. Enrolls Fifth Participant at Vancouver General Hospital in International Phase-2 Clinical Trial for Critical Limb Ischemia

Hemostemix Inc. announced that in the international phase-2 clinical trial for critical limb ischemia (CLI): treatment at Vancouver General Hospital of the site's fifth participant. The double-blind, randomized, placebo-controlled trial currently recruits participants at six sites in Canada and South Africa under the same clinical protocol and to date has enrolled 15 out of approximately 100 participants with CLI. The trial studies the efficacy of the company's lead product, ACP-01, which uses angiogenic progenitor cells to combat the life-threatening complications of CLI. These proprietary cells are grown from a patient's own blood and, once injected into his or her diseased tissue, are able to support the formation of new blood vessels.

Hemostemix Inc. Prepares Investigational New Drug Application

Hemostemix Inc. announced that it has prepared an Investigational New Drug (IND) application for review by the U.S. Food and Drug Administration for the company's lead product ACP-01, a potential breakthrough stem-cell therapy for critical limb ischemia (CLI). The time frame for FDA review is approximately 30 days. CLI is a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEM:CN C$0.80 CAD -0.03

HEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HEM.
View Industry Companies
 

Industry Analysis

HEM

Industry Average

Valuation HEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 20.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMOSTEMIX INC, please visit www.hemostemix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.